Want to see JP:7774 full AI Analyst Report?
7774 Stock Chart & Stats
¥575.00
¥0.00(0.00%)
At close: 4:00 PM EST
¥575.00
¥0.00(0.00%)
Day’s Range― - ―
52-Week Range¥448.00 - ¥927.00
Previous CloseN/A
Volume17.40K
Average Volume (3M)73.98K
Market Cap
¥29.73B
Enterprise Value¥21.99B
Total Cash (Recent Filing)¥3.35B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Oct 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.84
Shares Outstanding40,610,200
10 Day Avg. Volume68,620
30 Day Avg. Volume73,976
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)4.75
Price to Sales (P/S)11.09
P/FCF Ratio-43.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27.9
Revenue Forecast (FY)¥5.05B
Bulls Say, Bears Say
Bulls Say
Low LeverageEffectively no debt materially reduces solvency and refinancing risk, preserving financial flexibility while the company develops and commercializes regenerative therapies. This conservative funding structure provides a durable buffer against operating volatility and limits interest-related pressure on future cash flows.
Substantial Equity BaseA substantial equity base gives J-TEC resources to absorb operating losses and continue funding its business without relying heavily on lenders. Although equity has declined, the remaining balance provides a meaningful cushion for commercialization activities and near-term financial resilience.
Regenerative Medicine PlatformThe company operates in a specialized regenerative medicine niche, combining approved product commercialization with cell processing and tissue-engineering expertise. This focused platform can support durable differentiation and multiple revenue avenues as clinical use and partner-related manufacturing activity develop.
Bears Say
Revenue ContractionThe reversal from strong 2024 growth to two consecutive years of declining revenue indicates weakening commercial momentum and limited near-term visibility. Sustained contraction could constrain investment capacity, reduce operating leverage, and make it harder for the company to scale its regenerative medicine platform.
Widening Net LossesThe sharp expansion in net losses after a profitable 2024 signals that current operations are not consistently covering the cost base. Persistent losses can erode the equity cushion, limit internally funded development, and increase dependence on existing resources while management pursues a return to profitability.
Accelerating Cash BurnIncreasing operating cash outflow, alongside negative free cash flow of 562.7M in 2026, shows that the business is consuming cash rather than funding itself. If this pattern persists, available balance-sheet resources may decline and constrain product commercialization, development spending, or strategic flexibility.
Japan Tissue Engineering Co., Ltd. News
7774 FAQ
What was Japan Tissue Engineering Co., Ltd.’s price range in the past 12 months?
Japan Tissue Engineering Co., Ltd. lowest stock price was ¥448.00 and its highest was ¥927.00 in the past 12 months.
What is Japan Tissue Engineering Co., Ltd.’s market cap?
Japan Tissue Engineering Co., Ltd.’s market cap is ¥29.73B.
When is Japan Tissue Engineering Co., Ltd.’s upcoming earnings report date?
Japan Tissue Engineering Co., Ltd.’s upcoming earnings report date is Oct 30, 2026 which is in 6 days.
How were Japan Tissue Engineering Co., Ltd.’s earnings last quarter?
Japan Tissue Engineering Co., Ltd. released its earnings results on Jul 30, 2026. The company reported ¥1.29 earnings per share for the quarter.
Is Japan Tissue Engineering Co., Ltd. overvalued?
According to Wall Street analysts Japan Tissue Engineering Co., Ltd.’s price is currently Overvalued.
Does Japan Tissue Engineering Co., Ltd. pay dividends?
Japan Tissue Engineering Co., Ltd. does not currently pay dividends.
What is Japan Tissue Engineering Co., Ltd.’s EPS estimate?
Japan Tissue Engineering Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Japan Tissue Engineering Co., Ltd. have?
Japan Tissue Engineering Co., Ltd. has 40,610,200 shares outstanding.
What happened to Japan Tissue Engineering Co., Ltd.’s price movement after its last earnings report?
Japan Tissue Engineering Co., Ltd. reported an EPS of ¥1.29 in its last earnings report. Following the earnings report the stock price went up 9.091%.
Which hedge fund is a major shareholder of Japan Tissue Engineering Co., Ltd.?
Currently, no hedge funds are holding shares in JP:7774
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Japan Tissue Engineering Co., Ltd.
Japan Tissue Engineering Co., Ltd. operates within the regenerative medicine sector in Japan. The company's activities are organized into three core divisions: Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support. It manufactures and delivers autologous cultured tissues, such as epidermis, cartilage, corneal epithelium, and oral mucosal epithelium, to medical institutions for therapeutic applications. The firm also produces other advanced tissue-engineered medical products. Furthermore, Japan Tissue Engineering is involved in the research and development of three-dimensional human cultured tissue models, which are utilized in the development of external-use cosmetics and drugs, as well as for scientific investigations concerning skin and corneal tissues. Additionally, the company provides comprehensive contract development and manufacturing services for regenerative medicine. Established in 1999, Japan Tissue Engineering Co., Ltd. is based in Gamagori, Japan, and functions as a subsidiary of Teijin Limited.